Psoriasis Biologics Face Off in Drug Survival Study 

• by Julie Greenbaum

• January 14, 2026

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations

• by Małgorzata Kowacka, Michał Dec, Hubert Arasiewicz

• May 20, 2026

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

• by Kathryn Wighton

• June 29, 2026

• 3 min

Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease

• by Xiaoou Wang, Jitong Li, Keying Yu, Xianbo Wu, Quan Luo

• June 26, 2026